Physician profile
Michelle Levy
NPI 1932273869
$1,760.42
in general payments reported to CMS, 2019-2025
19 companies · $624 in 2025
The $624 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $75.75 · 2023: $404 · 2024: $657 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603 · Education: $81.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.02 |
| Education | $81.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $554.99 | 2023-2025 | Tremfya |
| Abbvie INC. | $252.00 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $161.05 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $154.11 | 2022-2025 | Absorica Ld, Winlevi |
| Mayne Pharma Commercial LLC | $145.86 | 2023-2025 | |
| Amgen INC. | $100.65 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $71.94 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $49.79 | 2024-2025 | Nemluvio |
| Almirall LLC | $43.97 | 2023-2024 | Seysara |
| Dermavant Sciences, INC. | $42.07 | 2023 | Vtama |
| Lilly USA, LLC | $24.76 | 2025 | Ebglyss, Taltz |
| Botanix Sb INC | $24.26 | 2025 | Sofdra |
| Genzyme Corporation | $23.64 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $20.90 | 2024 | Fraxel, Clear & Brilliant |
| Regeneron Healthcare Solutions, INC. | $20.79 | 2023 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $18.76 | 2025 | Spinosad, Natroba |
| Biofrontera INC. | $18.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.13 | 2023 | Sotyktu |
| Journey Medical Corporation | $15.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.